SCHEMBL277183

SCHEMBL277183

COC(=O)c1ccc(C(=O)NCCN2CCCC2)s1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
NPSR1 Q6W5P4 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GLA P06280 1/20 0.51
CYP2D6 P10635 2/20 0.50
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
DRD2 P14416 2/20 0.47
DRD4 P21917 2/20 0.47
DRD3 P35462 2/20 0.47
ACKR3 P25106 1/20 0.47
KDM4E B2RXH2 2/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL277405 0.88 KMT2A (0.61) POLBL3MBTL1GLAALDH1A1CYP2C9
SCHEMBL277129 0.86 ALDH1A1 (0.52) POLBNPSR1L3MBTL1GLACYP2D6
SCHEMBL279975 0.84 NPSR1 (0.58) POLBNPSR1L3MBTL1SMN1; SMN2GLA
SCHEMBL12124293 0.83 NPSR1 (0.57) POLBNPSR1L3MBTL1SMN1; SMN2GLA
SCHEMBL1587972 0.79 HPGD (0.50) NPSR1L3MBTL1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL2001834 0.79 NPSR1 (0.50) POLBNPSR1L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL8592457 0.79 TSHR (0.57) POLBALDH1A1CYP2C9KMT2AHPGD
SCHEMBL23983000 0.76 DRD2 (0.53) POLBSMN1; SMN2MEN1KMT2ADRD2
SCHEMBL12124272 0.76 DRD2 (0.60) POLBNPSR1L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL16011515 0.76 HDAC1 (0.61) POLBNPSR1L3MBTL1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
CN-101076519-A Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL IND LTD (JP) 2007-11-21 CN disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL POLB 4352/4885NPSR1 168/4885L3MBTL1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.